Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Emil D. Kakkis, M.D., Ph.D., the company's CEO and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The webcast will be accessible from the company’s website, with a replay available for 30 days.

NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 42^nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 PM PT.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

FAQ

What is the name of the company presenting at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024?

Ultragenyx Pharmaceutical Inc. is presenting at the conference.

What is the ticker symbol of Ultragenyx Pharmaceutical Inc.?

The ticker symbol is RARE.

Who will be presenting at the conference on behalf of Ultragenyx Pharmaceutical Inc.?

Emil D. Kakkis, M.D., Ph.D., the company's CEO and president, will be presenting.

Where can the webcast of the presentation be accessed?

The webcast will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

How long will the replay of the webcast be available?

The replay of the webcast will be available for 30 days.